ProCE Banner Events

Share

Relapsed/Refractory CLL/SLL and MCL: Training and Resources to Optimize Outcomes

Interact with an expert during a 1-hour, CME/CE-certified live meeting  focused on best practices and emerging strategies in the use of BTK inhibitors to treat relapsed/refractory CLL/SLL and MCL. Register today!

To Register: On the events dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar. 

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Registration not open

Credits Available

1.0

Who Should Attend

This program is intended for hematologists, medical oncologists, nurse practitioners, physician associates/physician assistants, pharmacists, nurses, and other healthcare professionals who care for patients with CLL/SLL or MCL.

Time and location

Tuesday, November 28, 2023

11:30 AM - 12:30 PM Central Time (CT)

Virtual

Private Event | Virtual Group
Norman, Oklahoma

Agenda

  • Current BTK inhibitor indications and guideline recommendations for R/R CLL and MCL
    o    Mechanisms of action
    o    Comparative efficacy and safety profiles
    o    Emerging data
  • Case challenges: selecting and sequencing BTK inhibitor therapy in R/R CLL/SLL and R/R MCL 
  • Clinical pearls and insights
  • The future of BTK inhibitor therapy: emerging strategies and approvals

Location

Venue Name

Private Event | Virtual Group

Address

Private Event | Virtual Group
Norman, Oklahoma

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners to optimize treatment with BTK inhibitors in caring for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL.

Target Audience
This program is intended for hematologists, medical oncologists, nurse practitioners, physician associates/physician assistants, pharmacists, nurses, and other healthcare professionals who care for patients with CLL/SLL or MCL. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate differences between covalent and noncovalent BTKi in terms of molecular characteristics, selectivity, clinical data, approved indications, dosing, safety profiles, and efficacy and their respective impact on clinical practice
  • Plan BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL, taking into consideration current indications, expert and guideline recommendations, and recent practice-changing clinical trial evidence
  • Implement evidence-based therapy for patients with resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes
  • Optimally manage adverse events associated with BTKi-based therapies considering safety profiles unique to each agent and regimen
  • Identify patients with R/R MCL and R/R SLL/SLL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations 

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-218-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate/Physician Assistant Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

This activity is supported by an educational grant from Lilly.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.